Efficacy of Ketanserin in the Therapy of Raynaud's Phenomenon: Thermometric Data

Abstract

After a two-week washout (WO) period with placebo 1 capsule/ bid, 12 patients suffering from stable Raynaud's phenomenon were treated with ketanserin (K) 40 mg/ bid for fifteen days. Blood pressure, heart rate, and laboratory parameters were evaluated at the end of each period. Patients used diary cards to record the number, duration, and intensity of attacks. Computerized thermometry of the fingers was evaluated at basal temperature after acclimatization, 23°C for thirty minutes; after cold test, 10°C for five minutes; and after thermal recovery, 23°C for eighteen minutes. Results were analyzed statistically by use of Student's t-test for paired data (p<0.05). No marked changes were observed in the symptoms of the attacks, but K proved effective in significantly reducing the number and duration of daily attacks and in promoting their spontaneous regression. Thermometry revealed a parallel increase in temperatures, particularly basal and recovery values. The data suggest increased flow and decreased vasospasm following 5-HT2 receptor blockade.

Get full access to this article

View all access options for this article.

References

Van Nueten JM , Janssens WJ : Augmentation of vasconstrictor responses to serotonin by acute and chronic factors: inhibition by ketanserin. J Hypertens 4:S55-S59, 1986.

Arneklo-Nobin B. , Nobin A. , Owman C. , et al: Serotonergic mechanisms in isolated human peripheral arteries and veins. J Cardiovasc Pharmacol 7:52-55, 1985.

Van Nueten JM : 5-Hydroxytyptamine and precapillary vessels . Fed Proc 42:223-227, 1983.

Van Nueten JM , DeRidder W. , Vanhoutte PM : Ketanserin and vascular contractions in response to cooling Eur J Pharmacol 99:321-332, 1984.

Perbellini L. , Apostoli P. , Gobbi M. , et al: La termometria computerizzata el'estesiometria cutanea delle mani nella diagnostica delle vasculopatie periferiche da strumenti vibranti. Med Lav 75:282-295, 1984.

Vanhoutte PM , Luscher T. : Serotonin and the blood vessel wall. J Hypertens 4 (suppl 1):S29-S35,, 1986.

Brouwer Rml , Wenting GJ , Visser W. , et al: Does serotonin receptor blockade have a therapeutic effect in Raynaud phenomenon? Vasa (suppl. 18):64-67, 1987.

Meloni F. , Transi MG , Sciacca V. , et al: Therapeutic efficacy ofketanserin, a selective antagonist of serotonin 2 (5-HT2) receptors in primary and secondary Raynaud's phenomenon . Angiology 38:530-536, 1987.

Arosio E. , Montesi G. , Zannoni M. , et al: Comparative efficacy of ketanserin and pentoxlphylline in treatment of Raynaud's phenomenon. Angiology 40: 633-638, 1989.

10.

Roald OK , Seem E. : Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J 289:577-579, 1984.

11.

Stranden E. , Roald OK , Krohg K. : Treatment of Raynaud's phenomenon with 5-HT2 receptor antagonist ketanserin. Br Med J 285:1069-1071, 1982.

12.

Jacobs Mjhm , Slaaf DW , Lemmens Haj , et al: The use of hemorheological and microcirculatory parameters in evaluating the effect of treatment in Raynaud's phenomenon. Vasc Surg 21:9-16, 1987.

13.

Arneklo-Nobin B. , Elmer O. , Akesson A. : Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud phenomenon. A double-blind placebo-controlled cross-over study . Int Angiology 7:19-25, 1988.